Inflammatory Biomarkers and Liver Histopathology in Non-Uremic and Uremic Chronic Hepatitis C Patients

Bengu Tatar1, Sukran Kose2, Emel Pala3

  • 1University of Health Science, Izmir Tepecik Education and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Izmir, Turkey. b.gtatar@hotmail.com.

Acta Medica (Hradec Kralove)
|October 5, 2017
PubMed

Insights

In chronic hepatitis C (cHepC) patients, YKL-40 and APRI score correlate with liver fibrosis. For those with end-stage renal disease (ESRD), APRI score may offer insights into fibrosis progression.

Area of Science:

  • Hepatology
  • Nephrology
  • Inflammation Research

Background:

  • Chronic hepatitis C (cHepC) is a significant cause of liver disease.
  • Assessing liver fibrosis and inflammation is crucial for managing cHepC.
  • Uremia in cHepC patients may alter disease progression and biomarker profiles.

Purpose of the Study:

  • To investigate the association between liver fibrosis and inflammation biomarkers.
  • To compare these associations in non-uremic versus uremic (ESRD) cHepC patients.

Main Methods:

  • Liver biopsy analysis using the modified ISHAC scoring system in 50 cHepC patients.
  • Measurement of inflammation markers: YKL-40, neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (PLR), CRP, and immunoglobulins (IgG, A, M).
  • Evaluation of AST to Platelet Ratio Index (APRI) score and fibrosis staging (FS).

Main Results:

  • cHepC patients exhibited elevated inflammation compared to healthy controls.
  • End-stage renal disease (ESRD) patients showed higher inflammation markers but lower fibrosis scores (FS) and hepatic activity index (HAI).
  • In non-uremic patients, YKL-40 and APRI score were independently associated with FS; in ESRD patients, only APRI score showed independent association with FS.

Conclusions:

  • YKL-40 and APRI score may serve as valuable non-invasive markers for liver fibrosis in non-uremic cHepC patients.
  • In cHepC patients with ESRD, APRI score appears more informative than other markers for predicting liver fibrosis.
  • Further research is needed to fully elucidate fibrosis prediction in cHepC patients with ESRD.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
630
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
963
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
272